Enclosed herewith results for Financial year FY 24-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evexia Lifecare Limited submitted audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, after a revised filing. Standalone revenue grew about 50.7% YoY to ₹8,402.33 lakhs, but net profit fell to ₹72.79 lakhs from ₹115.26 lakhs. Q4 standalone posted a net loss of ₹49.04 lakhs against a profit of ₹272.50 lakhs in Q4 FY24. Consolidated revenue jumped nearly 94% to ₹11,062.77 lakhs with net profit of ₹93.04 lakhs (down from ₹137.70 lakhs). The auditor issued a qualified opinion flagging material misstatements, poor books of account, improper valuation of investments, doubtful trade receivables, inadequate liquidity, and tax-related penalties. Standalone operating cash flow was sharply negative at ₹592.78 lakhs. The company also appointed Ms. Krupalibahen Rajeshbhai Mehta as Independent Director for 5 years. Two subsidiaries and one associate were excluded from consolidation due to unavailable financials.
Despite strong top-line growth, declining profits, a Q4 standalone loss, negative operating cash flows, and a qualified audit opinion with serious concerns on books of account, liquidity, and tax compliance are significant red flags for shareholders. The stock is likely to face negative sentiment and heightened regulatory scrutiny.